Treatment optimisation: making cancer treatment accessible and sustainable in Europe (lunch meeting)
24 September 2025 @ 12:00 - 14:00
Brussels, Belgium (hybrid)
The oncology academic community is sounding the alarm on the overuse of anti-cancer drugs. Optimal doses, treatment durations, sequences, and combinations of new anti-cancer drugs are often not identified at the time of marketing authorisation. Therefore, patients are experiencing unnecessary side effects and healthcare budgets are pressured by avoidable costs.
To address this situation, independent clinical research beyond market access must be facilitated. The role of the academic sector is needed to generate independent evidence that will guide clinicians to the optimal use of anti-cancer drugs. Treatment optimisation clinical trials, such as those focusing on treatment de-escalation, are key.
This event organised by EORTC and hosted by Mrs Tilly Metz (Greens), co-hosted by Mrs Romana Jerkovic (S&D) at the European Parliament will bring together various stakeholders to discuss the challenges and solutions for optimising cancer treatment in Europe.
In-person registration is now closed. Online participation remains open until 23 September 2025.
This is a hybrid event, lunch will be served to in-person participants. Please note that in-person participation will be subject to confirmation by 12 September 2025 because of the limited capacity of the venue. There is no restriction to online participation.
Speakers
Agenda
Treatment optimisation: making cancer treatment accessible and sustainable in Europe
12:00-14:00, 24 September 2025, European Parliament, Brussels, Belgium
| Time | Topic and speaker |
|---|---|
| 12:00 | Welcome and introduction “Better use of therapies for efficient and sustainable care in Europe” (T. Metz, MEP) |
| 12:05 | Why treatment optimisation is important for European citizens? (R Jerkovic, MEP) |
| 12:10 | Setting the scene “What is treatment optimisation and why do we need it?” (D. Lacombe, EORTC) |
| 12:20 | Panel discussion “Are we using therapies optimally in Europe?” Moderator: Y. Natsis (ESIP)
|
| 13:05 | Panel discussion “What are the possible solutions?” Moderator: F. Hulstaert (KCE)
|
| 13:50 | Wrap up and conclusion (T. Metz, MEP, D. Lacombe, EORTC) |
| 14:00 | End |


Next events
EORTC Pathobiology Autumn Group Meeting 2026
3 September - 4 September
Gmunden, Austria
EORTC Gastrointestinal Tract Cancer Group Autumn Meeting 2026
4 September - 5 September
Oxford, UK
EORTC Thyroid Cancer Group Autumn Meeting 2026
4 September
Porto, Portugal
SISAQOL pilot in-person training 2026
22 September - 23 September
Zagreb, Croatia
EORTC Brain Tumour Group Autumn Meeting 2026
23 September
Rome, IT











